GTM-MQNC2Z4
Skip to main content

White Paper

White Paper

Life science companies are developing cutting-edge medicines, medical devices, and therapies that entail increasingly complex clinical trials. As a result, regulators throughout the world have to step up their vigilance…

It's estimated that the average cost of developing a new drug has increased from $1 billion in 2010 to $1.1 billion in 20121. A big part of the cost can be attributed to clinical research, which typically lasts at least eight-and-a-half years. Given the enormous cost, time, and effort involved in clinical research, sponsors and CROs need to mitigate risks and…

The growth of contract research organizations (CROs) as an industry is inevitable. When the global economy is thriving, life science companies are inclined to develop more products and hire CROs…

The primary objective of any clinical trial is to determine the clinical safety and efficacy of an investigational product. One critical component of obtaining conclusive data is…

Quality, compliance, time, and cost are all critical concerns for life science companies conducting clinical trials. Given the skyrocketing price of clinical research, coupled with the current global economic downturn, the cost sometimes trumps other concerns…

CDISC Interchange